Fusion Antibodies plc announced Tim Watts, Non-executive Director since December 2017, has informed the Board of his intention to retire and, therefore, will not be seeking re-election at the AGM. He will cease to be a Director of the Company at the close of the AGM. Colin Walsh, Non-executive Director will take up the position of Chair of the Company's Audit Committee in place of Tim Watts.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 GBX | 0.00% | -9.33% | -20.00% |
23/05 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
23/05 | Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.00% | 4.13M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- FAB Stock
- News Fusion Antibodies plc
- Fusion Antibodies plc Announces Director Changes